Immuron Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Steve Lydeamore

Chief executive officer

AU$599.1k

Total compensation

CEO salary percentage	72.7%
CEO tenure	2.4yrs
CEO ownership	n/a
Management average tenure	5.9yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Lydeamore's remuneration changed compared to Immuron's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$599k	AU$436k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$4m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$584k	AU$415k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$3m
Dec 31 2022	n/a	n/a	-AU$3m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$781k	AU$6k	-AU$3m

Compensation vs Market: Steve's total compensation ($USD388.87K) is above average for companies of similar size in the Australian market ($USD298.48K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Lydeamore (56 yo)

2.4yrs

Tenure

AU$599,135

Compensation

Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as Chief Executive Officer at Immuron Limited since June 27, 2022. He served as the Chief Executive Officer of Anatara Lifesciences Limite...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Lydeamore	Chief Executive Officer	2.4yrs	AU$599.14k	no data
Jerry Kanellos	Chief Operating Officer	9.3yrs	AU$359.25k	0.15% A$ 25.6k
Flavio Palumbo	Chief Commercial Officer	2yrs	AU$347.61k	no data
Phillip Hains	CFO & Company Secretary	11.6yrs	no data	0.36% A$ 62.9k
David Lyon	Head of Marketing	no data	no data	no data

5.9yrs

Average Tenure

59.5yo

Average Age

Experienced Management: IMC's management team is seasoned and experienced (5.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Glenn Tillotson	Member of Advisory Board	no data	no data	no data
Jeannette Joughin	Independent Non-Executive Director	less than a year	AU$7.55k	0% A$ 0
Daniel Pollock	Independent Non-Executive Director	12.1yrs	AU$127.65k	0.36% A$ 63.0k
Paul Brennan	Independent Non-Executive Chairman	2.7yrs	AU$153.60k	0% A$ 0
Dena Lyras	Member of Advisory Board	no data	no data	no data
Ravi Savarirayan	Independent Non-Executive Director	7.6yrs	AU$75.00k	0.38% A$ 67.6k
Sahil Khanna	Member of Advisory Board	no data	no data	no data
Paul Feuerstadt	Member of Advisory Board	no data	no data	no data
Teena Chopra	Member of Advisory Board	no data	no data	no data

5.1yrs

Average Tenure

63yo

Average Age

Experienced Board: IMC's board of directors are considered experienced (5.1 years average tenure).

Immuron Management

Management criteria checks 2/4

Key information

Recent management updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited, Annual General Meeting, Nov 21, 2023

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

New major risk - Share price stability

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Insufficient new directors

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.87

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age